STOCK TITAN

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Harmony Biosciences (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference/b) in New York on .

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Harmony Biosciences (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference/b) in New York on . A live webcast will be accessible via the investor page of the Harmony Biosciences website.

The company focuses on developing and commercializing therapies for patients with rare neurological diseases and is headquartered in Plymouth Meeting, Pennsylvania.

Loading...
Loading translation...
Argus Aug 27 session
+0.53% close to close Open Argus
Details

News Market Reaction – HRMY

On Aug 27, the day this news came out, HRMY closed 0.53% above the previous close.

Data tracked by StockTitan Argus for the Aug 27 session.

Key Figures

Conference Date: September 10, 2026 Fireside Chat Time: 10:20 a.m. ET
Conference Date
September 10, 2026
2026 Cantor Global Healthcare Conference
Fireside Chat Time
10:20 a.m. ET
September 10, 2026 conference appearance

Historical Context

5 past events · Latest: Aug 06
5 events
  1. Aug 06

    Conference participation

    24h Move
    +1.3%

    Management announced participation in the Piper Sandler Virtual CNS Symposium.

  2. Aug 04

    Clinical data

    24h Move
    +8.9%

    Q2 revenue growth accompanied initial BP-205 Phase 1 clinical data.

  3. Jul 21

    Earnings scheduling

    24h Move
    +10.0%

    The company scheduled its second-quarter 2026 financial results release.

  4. Jul 16

    Revenue and leadership

    24h Move
    -3.9%

    Record preliminary revenue and reaffirmed guidance accompanied a CFO transition.

  5. Jun 11

    Portfolio transaction

    24h Move
    -0.8%

    Paragon closed the sale of Emalex Biosciences to Teva Pharmaceutical.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.

A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Harmony Biosciences (HRMY) present at the 2026 Cantor Global Healthcare Conference?

Harmony Biosciences will participate in a fireside chat on Thursday, September 10, 2026, at 10:20 a.m. ET. According to Harmony Biosciences, this session is part of the 2026 Cantor Global Healthcare Conference in New York.

How can investors access the Harmony Biosciences (HRMY) webcast for the Cantor 2026 conference?

Investors can access the webcast on the investor page of the Harmony Biosciences website. According to Harmony Biosciences, a live webcast of the September 10, 2026 fireside chat will be made available online.

What type of event is Harmony Biosciences (HRMY) joining at the 2026 Cantor Global Healthcare Conference?

Harmony Biosciences management will join a fireside chat session at the conference. According to Harmony Biosciences, this discussion will occur in New York on September 10, 2026, and will be webcast through the company’s investor relations site.

What does Harmony Biosciences (HRMY) do in the rare neurological disease space?

Harmony Biosciences is a pharmaceutical company focused on therapies for rare neurological diseases with unmet medical needs. According to Harmony Biosciences, it develops and commercializes innovative treatments driven by novel science and a patient-centered approach.

Where is Harmony Biosciences (HRMY) headquartered and when was it established?

Harmony Biosciences is headquartered in Plymouth Meeting, Pennsylvania and was established in 2017. According to Harmony Biosciences, it was founded by Paragon Biosciences and focuses on innovative therapies for rare neurological conditions.

How can investors contact Harmony Biosciences (HRMY) investor relations about the 2026 Cantor conference?

Investors can contact Harmony Biosciences investor relations via Brennan Doyle at 484-566-3685 or bdoyle@harmonybiosciences.com. According to Harmony Biosciences, these details are provided for investor-related inquiries, including conference participation.

Keep reading